Reset filter
Keywords
Type 2 Diabetes ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

198 Search results.
Relevance Rating New first Old first

Eligibility Type 2 Diabetes NCT01939782

- 9/2/15 - 1 form, 3 itemgroups, 40 items, 1 language
Itemgroups: Inclusion Criteria, Inclusion Criteria, Exclusion Criteria
Metabolic Clock Genes During Fasting and After Food Intake in Type 2 Diabetics; ODM derived from: https://clinicaltrials.gov/show/NCT01939782 Principal Investigator: Daniela Jakubowicz, MD Diabetes Unit E. Wolfson Medical Center. Tel Aviv University

Eligibility Type 2 Diabetes Mellitus NCT00254254

- 4/30/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT00254254

Eligibility Diabetes Mellitus Type 2 NCT00822367

- 4/10/17 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Blood Sugar Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00822367

Eligibility Type 2 Diabetes Weight Loss NCT01601574

- 6/23/21 - 1 form, 2 itemgroups, 39 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Weight Loss Study for People With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01601574

Eligibility Type 2 Diabetes NCT01408628

- 4/18/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The I-KAN Study: Internet Insulin Education for Kansans; ODM derived from: https://clinicaltrials.gov/show/NCT01408628

dbGaP phs000408 eMERGE Genome-Wide Association Studies of Obesity - Eligibility

- 10/12/22 - 5 forms, 1 itemgroup, 11 items, 1 language
Itemgroup: IG.elig
Principal Investigator: Glenn S. Gerhard, MD, Weis Center for Research, Geisinger Clinic, Danville, PA, USA MeSH: Type 2 Diabetes,Obesity,Bariatric Surgery https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000408 The Geisinger eMERGE Genome-Wide Association Studies of Obesity Project is a genetic study of a cohort of primarily Caucasian patients with extreme obesity who have undergone bariatric surgery. Roux-en-Y gastric bypass (RYGB) surgery, in which intestinal anatomy is altered, dramatically ameliorates and/or eliminates Type 2 diabetes mellitus (T2D) in 50-80% of patients within hours to days following surgery, well before significant weight loss, in contrast to other types of bariatric surgeries, such as gastric banding, that attenuate insulin resistance as a result of substantial weight loss that occurs over months to years. The molecular mechanism by which RYGB exerts this clinical phenomenon occurs is not known. The goal of this project was to conduct a genome-wide association study (GWAS) to identify genetic variants associated with amelioration in T2D defined by medication independence. Identifying genetic variants that influence the dramatic resolution of T2D from RYGB may identify novel targets for pharmacological T2D therapies and/or identify patients in whom RYGB may not be effective.

pht002438.v1.p1

1 itemgroup 5 items

pht002439.v1.p1

1 itemgroup 4 items

pht002440.v1.p1

1 itemgroup 24 items

pht002441.v1.p1

1 itemgroup 4 items

dbGaP phs000380 eMERGE Genome-Wide Association Studies of Obesity (Metabochip) - Eligibility

- 10/12/22 - 5 forms, 1 itemgroup, 11 items, 1 language
Itemgroup: IG.elig
Principal Investigator: Glenn S. Gerhard, MD, Weis Center for Research, Geisinger Clinic, Danville, PA, USA MeSH: Type 2 Diabetes,Obesity,Bariatric Surgery https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000380 The Geisinger eMERGE Genome Wide Association Studies of Obesity (Metabochip) Project is a genetic study of a cohort of primarily Caucasian patients with extreme obesity who have undergone bariatric surgery. Roux-en-Y gastric bypass (RYGB) surgery, in which intestinal anatomy is altered, dramatically ameliorates and/or eliminates Type 2 diabetes mellitus (T2D) in 50-80% of patients within hours to days following surgery, well before significant weight loss, in contrast to other types of bariatric surgeries, such as gastric banding, that attenuate insulin resistance as a result of substantial weight loss that occurs over months to years. The molecular mechanism by which RYGB exerts this clinical phenomenon is not known. The goal of this project was to conduct a genome wide association study (GWAS) to identify genetic variants associated with amelioration in T2D defined by medication independence. Identifying genetic variants that influence the dramatic resolution of T2D from RYGB may identify novel targets for pharmacological T2D therapies and/or identify patients in whom RYGB may not be effective.

pht002456.v1.p1

1 itemgroup 4 items

pht002457.v1.p1

1 itemgroup 4 items

pht002458.v1.p1

1 itemgroup 25 items

pht002459.v1.p1

1 itemgroup 3 items

Eligibility Type 2 Diabetes NCT02490085

- 6/30/16 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02490085

Eligibility Type 2 Diabetes NCT02301806

- 9/20/21 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM; ODM derived from: https://clinicaltrials.gov/show/NCT02301806

Eligibility Type 2 Diabetes NCT02046395

- 12/31/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT02046395

Eligibility Type 2 Diabetes NCT02459496

- 1/19/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Diabetological Dietary Strategies and Perspectives / DDS-P (Deutsche Diabetes-Studie Potsdam); ODM derived from: https://clinicaltrials.gov/show/NCT02459496

Eligibility Type 2 Diabetes NCT01072565

- 1/19/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring; ODM derived from: https://clinicaltrials.gov/show/NCT01072565

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial